Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main takeaway here is that Tempus' core business is expected to grow ...

Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in Q4 2024, with gross profit growth accelerating to 49.7%. The company ...

Please go ahead. Thank you, Jason. Good afternoon and welcome to Tempus' Fourth Quarter 2024 Conference Call. This afternoon Tempus released results for the quarter and year ended December 31 ...

These speculations have surged in the past month after her investment in AI healthcare firm Tempus AI (NASDAQ:TEM) surged over 300% since 14th January. According to the latest periodic transaction ...

Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM stock by buying 50 of ...

Tempus AI has raised an additional $300 million in incremental debt financing from alternative investment manager Ares Management that is intended to support the firm's recent acquisition of Ambry ...

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics ("Ambry"), which closed on February 3, 2025. Combined with $260 million of capital provided in ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom ...

Tempus AI (NASDAQ: TEM) is a leader in precision medicine and artificial intelligence (AI) in the healthcare sector. Tempus AI’s stock price has seen an increase, with gains of over 160% in the ...